LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1α via upregulation of VHL in a colon cancer cell line

Biochemical Pharmacology

Volumn 80, Issue 7, 2010, Pages 982-989

  Lee, Kyeong ^a,b   Kang, Jung Eun ^b,c   Park, Song Kyu ^b   Jin, Yinglan ^a,b   Chung, Kyung Sook ^b   Kim, Hwan Mook ^b   Lee, Kiho ^b   Kang, Moo Rim ^b   Lee, Myung Kyu ^b   Song, Kyung Bin ^d   Yang, Eun Gyeong ^e   Lee, Jung Jun ^b   Won, Misun ^b,c  

^a Dongguk University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c University of Science and Technology (UST)   (South Korea)

^d Chungnam National University   (South Korea)

^e Korea Institute of Science and Technology   (South Korea)

Author keywords

(aryloxyacetylamino)Benzoic acid; HIF 1 ; Hypoxia; Prolyl hydroxylation; Von Hippel Lindau

Indexed keywords

(ARYLOXYACETYLAMINO)BENZOIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; LW 6; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TOPOTECAN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; ARNT PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1; OXYGEN; PROTEASOME; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HYDROXYLATION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN STABILITY; UPREGULATION; WILD TYPE; XENOGRAFT; ANIMAL; CELL LINE; COLON TUMOR; GENETICS; METABOLISM; NUDE MOUSE; VON HIPPEL LINDAU DISEASE;

ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; CELL LINE; COLONIC NEOPLASMS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; OXYGEN; PROCOLLAGEN-PROLINE DIOXYGENASE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; UP-REGULATION; VON HIPPEL-LINDAU DISEASE;

EID: 77955656201     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.06.018     Document Type: Article

References (44)

1. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
2. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59:5830-5835.
3. Semenza G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007, 12:853-859.
4. Pili R., Donehower R.C. Is HIF-1 alpha a valid therapeutic target?. J Natl Cancer Inst 2003, 95:498-499.
5. Eguchi H., Ikuta T., Tachibana T., Yoneda Y., Kawajiri K. A nuclear localization signal of human aryl hydrocarbon receptor nuclear translocator/hypoxia-inducible factor 1beta is a novel bipartite type recognized by the two components of nuclear pore-targeting complex. J Biol Chem 1997, 272:17640-17647.
6. Pollenz R.S., Sattler C.A., Poland A. The aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator protein show distinct subcellular localizations in Hepa 1c1c7 cells by immunofluorescence microscopy. Mol Pharmacol 1994, 45:428-438.
7. Seagroves T., Johnson R.S. Two HIFs may be better than one. Cancer Cell 2002, 1:211-213.
8. Lal A., Peters H., St Croix B., Haroon Z.A., Dewhirst M.W., Strausberg R.L., et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 2001, 93:1337-1343.
9. Kubo T., Maezawa N., Osada M., Katsumura S., Funae Y., Imaoka S., et al. an environmental endocrine-disrupting chemical, inhibits hypoxic response via degradation of hypoxia-inducible factor 1alpha (HIF-1alpha): structural requirement of bisphenol A for degradation of HIF-1alpha. Biochem Biophys Res Commun 2004, 318:1006-1011.
10. Shin D.H., Kim J.H., Jung Y.J., Kim K.E., Jeong J.M., Chun Y.S., et al. Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 2007, 255:107-116.
11. Yeo E.J., Chun Y.S., Park J.W. New anticancer strategies targeting HIF-1. Biochem Pharmacol 2004, 68:1061-1069.
12. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002, 62:4316-4324.
13. Belozerov V.E., Van Meir E.G. Hypoxia inducible factor-1: a novel target for cancer therapy. Anti-cancer Drugs 2005, 16:901-909.
14. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002, 111:709-720.
15. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001, 292:464-468.
16. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitilation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
17. Kallio P.J., Wilson W.J., O'Brien S., Makino Y., Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 1999, 274:6519-6525.
18. Salceda S., Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997, 272:22642-22647.
19. Kaluzova M., Kaluz S., Lerman M.I., Stanbridge E.J. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol Cell Biol 2004, 24:5757-5766.
20. Liu Y.V., Baek J.H., Zhang H., Diez R., Cole R.N., Semenza G.L. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 2007, 25:207-217.
21. Lee K., Lee J.H., Boovanahalli S.K., Jin Y., Lee M., Jin X., et al. (Aryloxyacetylamino)benzoic acid analogues: a new class of hypoxia-inducible factor-1 inhibitors. J Med Chem 2007, 50:1675-1684.
22. Kim D.M., Chung K.S., Choi S.J., Jung Y.J., Park S.K., Han G.H., et al. RhoB induces apoptosis via direct interaction with TNFAIP1 in HeLa cells. Int J Cancer 2009, 125:2520-2527.
23. Chung K.S., Jang Y.J., Kim N.S., Park S.Y., Choi S.J., Kim J.Y., et al. Rapid screen of human genes for relevance to cancer using fission yeast. J Biomol Screen 2007, 12:568-577.
24. Nam J.O., Kim J.E., Jeong H.W., Lee S.J., Lee B.H., Choi J.Y., et al. Identification of the alphavbeta3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect. J Biol Chem 2003, 278:25902-25909.
25. Kuo C.J., LaMontagne K.R., Garcia-Cardena G., Ackley B.D., Kalman D., Park S., et al. Oligomerization-dependent regulation of motility and morphogenesis by the collagen XVIII NC1/endostatin domain. J Cell Biol 2001, 152:1233-1246.
26. Won M.S., Im N., Park S., Boovanahalli S.K., Jin Y., Jin X., et al. A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway. Biochem Biophys Res Commun 2009, 385:16-21.
27. Cho H., Park H., Yang E.G. A fluorescence polarization-based interaction assay for hypoxia-inducible factor prolyl hydroxylases. Biochem Biophys Res Commun 2005, 337:275-280.
28. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000, 14:34-44.
29. Puppo M., Battaglia F., Ottaviano C., Delfino S., Ribatti D., Varesio L., et al. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Mol Cancer Ther 2008, 7:1974-1984.
30. Berchner-Pfannschmidt U., Tug S., Trinidad B., Oehme F., Yamac H., Wotzlaw C., et al. Nuclear oxygen sensing: induction of endogenous prolyl-hydroxylase 2 activity by hypoxia and nitric oxide. J Biol Chem 2008, 283:31745-31753.
31. Berchner-Pfannschmidt U., Yamac H., Trinidad B., Fandrey J. Nitric oxide modulates oxygen sensing by hypoxia-inducible factor 1-dependent induction of prolyl hydroxylase 2. J Biol Chem 2007, 282:1788-1796.
32. Kaelin W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002, 2:673-682.
33. Los M., Jansen G.H., Kaelin W.G., Lips C.J., Blijham G.H., Voest E.E. Expression pattern of the von Hippel-Lindau protein in human tissues. Laboratory investigation. J Tech Methods Pathol 1996, 75:231-238.
34. Linehan W.M., Vasselli J., Srinivasan R., Walther M.M., Merino M., Choyke P., et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004, 10:6282S-6289S.
35. Kapitsinou P.P., Haase V.H. The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Diff 2008, 15:650-659.
36. Jung C.R., Hwang K.S., Yoo J., Cho W.K., Kim J.M., Kim W.H., et al. E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat Med 2006, 12:809-816.
37. Akiyama H., Tanaka T., Itakura H., Kanai H., Maeno T., Doi H., et al. Inhibition of ocular angiogenesis by an adenovirus carrying the human von Hippel-Lindau tumor-suppressor gene in vivo. Invest Ophthalmol Visual Sci 2004, 45:1289-1296.
38. Jones M.K., Szabo I.L., Kawanaka H., Husain S.S., Tarnawski A.S. von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB J 2002, 16:264-266.
39. Kuroki T., Trapasso F., Yendamuri S., Matsuyama A., Alder H., Mori M., et al. Allele loss and promoter hypermethylation of VHL, RAR-beta RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 2003, 63:3724-3728.
40. Alleman W.G., Tabios R.L., Chandramouli G.V., Aprelikova O.N., Torres-Cabala C., Mendoza A., et al. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine. Clin Cancer Res 2004, 10:7011-7021.
41. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H., Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004, 64:1475-1482.
42. Creighton-Gutteridge M., Cardellina J.H., Stephen A.G., Rapisarda A., Uranchimeg B., Hite K., et al. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res 2007, 13:1010-1018.
43. Zhou J., Schmid T., Frank R., Brune B. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J Biol Chem 2004, 279:13506-13513.
44. Hoffman R.M. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999, 17:343-359.